In short
This article provides information about ongoing clinical trials investigating new treatments for lichen planus, a chronic inflammatory condition affecting the skin and mucous membranes. Currently, there is one active trial testing the medication deucravacitinib in patients with this condition. The trial is taking place in Germany and aims to evaluate whether this investigational drug can reduce inflammation and improve symptoms in people living with lichen planus.
Clinical trial locations
Study on the Effectiveness of Deucravacitinib for Patients with Lichen Planus
This clinical trial is investigating whether a medication called deucravacitinib can help people with lichen planus, a condition that causes swelling, irritation, and characteristic purplish bumps on the skin, as well as lesions in the mouth and other mucous membranes. The condition can be uncomfortable and painful, particularly when it affects the inside of the mouth.
Main inclusion criteria: To participate in this study, individuals must be at least 18 years old and have lichen planus confirmed through a medical tissue test showing active symptoms. Participants need to have a certain level of disease activity measured by the Lichen Planus Activity and Damage Index, or LiPADI Activity Score. Specifically, they must have a score of 6 or higher, or 3 or higher if symptoms are only present in the mouth or other mucosal areas. All participants must be willing and able to follow study instructions, attend all required visits, and provide written informed consent after understanding the study details.
Main exclusion criteria: People who have other inflammatory conditions different from lichen planus cannot join the trial. The study also excludes individuals outside the specified age range and those considered part of vulnerable populations who might need special protection.
Focus and goal: The trial aims to determine whether deucravacitinib can effectively reduce the symptoms and activity of lichen planus compared to a placebo, which is an inactive tablet that looks identical to the medication but contains no active ingredient. The study follows participants over approximately 16 weeks, with regular visits to monitor their condition. The primary measure of success is the change in the LiPADI Activity Score from the beginning to the end of the study. Researchers will also look at changes in gene expression profiles and quality of life measures to better understand how the medication affects the condition.
Investigational drug: Deucravacitinib is the medication being tested in this trial. It works by selectively blocking an enzyme called TYK2, which plays a role in the immune system's inflammatory response. By inhibiting this enzyme, deucravacitinib may help reduce the inflammation that causes the uncomfortable symptoms of lichen planus. Participants take a 6 mg dose of the medication once daily by mouth in the form of a film-coated tablet throughout the study period.
Summary
Currently, there is one ongoing clinical trial for lichen planus, taking place in Germany. The trial focuses on testing deucravacitinib, a TYK2 inhibitor that targets the immune pathways involved in inflammation. This represents an important area of research as treatment options for lichen planus remain limited, particularly for patients with more severe or widespread disease. The trial is designed to provide evidence on whether this type of medication can offer relief to people living with this chronic inflammatory condition. Those interested in participating should speak with their healthcare provider to determine if they meet the eligibility criteria and to discuss potential benefits and risks of trial participation.
